Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma

International Journal of Cancer

Volumn 128, Issue 4, 2011, Pages 771-777

  Ma, Haiqing ^a   Liang, Xiaoting ^a   Chen, Yibing ^a   Pan, Ke ^a   Sun, Jiancong ^a   Wang, Hui ^a   Wang, Qijing ^a   Li, Yongqiang ^a   Zhao, Jingjing ^a   Li, Jianjun ^a   Chen, Minshan ^a   Xia, Jianchuan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

BATF2; downregulation; expression; hepatocellular carcinoma; prognosis

Indexed keywords

BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; PROTEIN BATF2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; TUMOR VOLUME; WESTERN BLOTTING;

ADULT; AGED; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 78650592166     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25407     Document Type: Article

References (12)

1. Okuda K,. Hepatocellular carcinoma. J Hepatol 2000; 32: 225-37.
2. El-Serag HB, Mason AC,. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
3. Chiriva-Internati M, Grizzi F, Wachtel MS, Jenkins M, Ferrari R, Cobos E, Frezza EE,. Biological treatment for liver tumor and new potential biomarkers. Dig Dis Sci 2008; 53: 836-43.
4. Su ZZ, Lee SG, Emdad L, Lebdeva IV, Gupta P, Valerie K, Sarkar D, Fisher PB,. Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN). Proc Natl Acad Sci USA 2008; 105: 20906-11.
5. Battifora H,. Assessment of antigen damage in immunohistochemistry. The vimentin internal control. Am J Clin Pathol 1991; 96: 669-71.
6. Williams JH, Mepham BL, Wright DH,. Tissue preparation for immunocytochemistry. J Clin Pathol 1997; 50: 422-8.
7. Qin LX, Tang ZY,. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 385-92.
8. Zender L, Kubicka S,. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma. Onkologie 2008; 31: 550-5.
9. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez NS, Chen X, Ahmed S, Konishi K, Hamilton SR, Issa JP,. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 2007; 104: 18654-9.
10. Oue N, Mitani Y, Motoshita J, Matsumura S, Yoshida K, Kuniyasu H, Nakayama H, Yasui W,. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer 2006; 106: 1250-9.
11. Kondoh N, Wakatsuki T, Hada A, Shuda M, Tanaka K, Arai M, Yamamoto M,. Genetic and epigenetic events in human hepatocarcinogenesis. Int J Oncol 2001; 18: 1271-8.
12. Singal R, Ginder GD,. DNA methylation. Blood 1999; 93: 4059-70.